-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, ASDwxY4y14dHztsLybFAV+1de1bEfNpfiRhLKBG2JWC++Oioi9Sn2fmzUXEXFgjn i0pUxwjyJaL8ZRHe+PFKlg== 0001019056-02-000074.txt : 20020414 0001019056-02-000074.hdr.sgml : 20020414 ACCESSION NUMBER: 0001019056-02-000074 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20020213 ITEM INFORMATION: Other events ITEM INFORMATION: Financial statements and exhibits FILED AS OF DATE: 20020213 FILER: COMPANY DATA: COMPANY CONFORMED NAME: FRESENIUS MEDICAL CARE HOLDINGS INC /NY/ CENTRAL INDEX KEY: 0000042872 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 133461988 STATE OF INCORPORATION: NY FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-03720 FILM NUMBER: 02542147 BUSINESS ADDRESS: STREET 1: TWO LEDGEMONT CENTER STREET 2: 95 HAYDEN AVE CITY: LEXINGTON STATE: MA ZIP: 02420 BUSINESS PHONE: 6174029000 FORMER COMPANY: FORMER CONFORMED NAME: GRACE W R & CO /CT/ DATE OF NAME CHANGE: 19900423 FORMER COMPANY: FORMER CONFORMED NAME: GRACE W R & CO /NY/ DATE OF NAME CHANGE: 19920703 FORMER COMPANY: FORMER CONFORMED NAME: FRESENIUS NATIONAL MEDICAL CARE HOLDINGS INC DATE OF NAME CHANGE: 19961015 8-K 1 fresen_8k.txt FORM 8-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ------------------------------ FORM 8-K CURRENT REPORT Pursuant to Sections 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 13, 2002 ----------------- FRESENIUS MEDICAL CARE HOLDINGS, INC. ----------------------------------------------------- (Exact name of registrant as specified in its charter) New York --------------------------------------------- (State or other jurisdiction of incorporation) 1-3720 13-3461988 - -------------------------------------------------------------------------------- (Commission File Number (IRS Employer Identification No.) 95 Hayden Avenue Lexington, Massachusetts 02420 - -------------------------------------------------------------------------------- (Address or principal executive offices) (Zip Code) Registrant's telephone number, including area codes: (781) 402-9000 -------------- Not Applicable - -------------------------------------------------------------------------------- (Former name or former address, if changed since last report) ITEM 5. Other Events On February 13, 2002, Fresenius Medical Care AG, the parent corporation of Fresenius Medical Care Holdings, Inc., announced a special charge to be taken in the fourth quarter of 2001. A copy of Fresenius Medical Care AG's Investor News release is attached as an exhibit to this report. ITEM 7. Financial Statements and Exhibits Exhibit 99 Investor News release dated February 13, 2002 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. FRESENIUS MEDICAL CARE HOLDINGS, INC. /s/ BEN J. LIPPS ------------------------------------------ DATE: February 13, 2002 Name: Ben J. Lipps Title: Chief Executive Officer 2 EX-99 3 ex99.txt EXHIBIT 99 [GRAPHIC OMITTED] Fresenius Medical Care FRESENIUS MEDICAL CARE AG INVESTOR NEWS INVESTOR RELATIONS Else-Kroner-Str. 1 D-61352 Bad Homburg Contact: Oliver Maier Phone: + 49 6172 609 2601 Fax: + 49 6172 609 2301 E-mail: ir-fms@fmc-ag.com North America: Heinz Schmidt Phone: + 1 781 402 9000 Ext.: 4518 Fax: + 1 781 402 9741 E-mail: ir-fmcna@fmc-ag.com Internet: http://www.fmc-ag.com --------------------- FEBRUARY 13, 2002 FRESENIUS MEDICAL CARE AG TO PROVIDE FOR 1996 MERGER-RELATED LEGAL MATTERS INCLUDING PENDING COMMERCIAL INSURER LITIGATION BY TAKING A SPECIAL CHARGE FOR 2001 Fresenius Medical Care AG (Frankfurt Stock Exchange: FME, FME3 - NYSE: FMS, FMS_p), the world's largest provider of dialysis products and services, today announced that it will accrue a special pre-tax charge of $ 258 million in the fourth quarter of 2001 ($ 177 million after tax) principally to address potential liabilities and legal expenses of the Company arising in connection with the W.R. Grace Chapter 11 proceedings AND the cost of resolving the pending litigation and other disputes with certain commercial insurers. Fresenius Medical Care AG also announced that the Company entered into an agreement in principle outlining terms of a process to resolve the pending litigation with Aetna Life Insurance Company and its affiliates (Aetna), one of the leading US commercial insurance companies. ********* The special charge primarily comprises two major components: 1. Fresenius Medical Care has assessed the extent of potential liabilities that the Company may be exposed to as a result of the W.R. Grace Chapter 11 proceedings, in particular pre-merger tax liabilities of W.R. Grace. Fresenius Medical Care will accrue $ 172 million pre-tax to provide for such potential liabilities and the costs of defending the Company in litigation arising out of W.R. Grace's Chapter 11 filing. The Company will continue to vigorously seek existing indemnification against these pre-merger liabilities from W.R. Grace and from Sealed Air Corporation, formerly known as Grace Holding, Inc. 2. Fresenius Medical Care has entered into an agreement in principle with Aetna to establish, among other things, a process for resolving its pending litigation and the basis for a cooperative relationship that will continue to improve renal patient care, reduce clinical costs and streamline administrative procedures. The Company is optimistic that these terms will also provide a basis for resolving pending matters with the remaining commercial litigants and has therefore included in the special charge an amount of $ 56 million pre-tax to provide for settlement obligations, legal expenses and disputed accounts receivable. If the Company is unable to settle the pending matters with any of the remaining commercial insurers, whether on the basis of the Aetna agreement in principle or otherwise, the Company believes that this charge reasonably estimates the costs and expenses associated with such litigation. The remaining amount of around $ 30 million pre-tax will be accrued for other 1996 merger-related legal issues. Ben Lipps, Chief Executive Officer of Fresenius Medical Care, commented, "we are pleased with these significant steps to provide for and resolve the remaining legal matters dating back to our 1996 National Medical Care transaction and we believe that this puts those matters financially behind us. We believe we found a model with Aetna that sets the stage for a productive relationship and I would like to compliment Aetna for its commitment to patient care and its willingness to work creatively with us. I am optimistic that this agreement will provide the basis to resolve similar disputes with other commercial insurers. We have worked hard since Grace filed for Chapter 11 in 2001 to assess the potential impact of that filing on the Company and to encourage Grace and its affiliates to honor the obligations they undertook to us in 1996. At the same time, we have carefully assessed the potential liabilities arising from that filing and the costs to enforce our legal rights. We continue to enforce vigorously our indemnification from W.R. Grace and Sealed Air Corporation and assert our rights under the law. With these steps to provide for resolution of the 1996 merger-related issues, we will continue our focus on operational excellence, strong financial performance and the transformation of Fresenius Medical Care from the largest worldwide provider of dialysis products and services to the leading renal therapy company." Fresenius Medical Care AG is to announce fourth quarter and full year 2001 results on March 5, 2002. The Company expects to achieve earnings after tax, excluding the special charge, to be in the range of $ 240 - 245 million for the fiscal year 2001. Fresenius Medical Care AG is the world's largest, integrated provider of products and services for individuals with chronic kidney failure, a condition that affects more than 1,000,000 individuals worldwide. Through its network of more than 1,375 dialysis clinics in North America, Europe, Latin America and Asia-Pacific, Fresenius Medical Care provides dialysis treatment to approximately 103,850 patients around the globe. Fresenius Medical Care is also the world's leading provider of dialysis products such as hemodialysis machines, dialyzers and related disposable products. For more information about Fresenius Medical Care, visit the Company's website at http://www.fmc-ag.com. --------------------- This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including changes in business, economic and competitive conditions, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG does not undertake any responsibility to update the forward-looking statements in this release. -----END PRIVACY-ENHANCED MESSAGE-----